Lido Advisors
ETON icon

Lido Advisors’s Eton Pharmaceutcials ETON Stock Holding History

Lido Advisors’s Portfolio ETON Stock Details ETON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-44,000
Closed -$169K – 1244
2023
Q1 		$169K Buy
+44,000
New +$160K ﹤0.01% 1031

Other funds holding ETON

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.43M AUM 17.52% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Lido Advisors's ETON Position: Q2 2023 in Review

Lido Advisors sold out of Eton Pharmaceutcials (ETON) in Q2 2023, closing a stake of 44,000 shares — an estimated $169K sold.

Lido Advisors first reported a position in ETON in Q1 2023 and held it in 1 quarter. The position peaked at $169K in Q1 2023. 33 funds tracked by Wall St. Rank hold ETON as of Q2 2023.

  • Lido Advisors reported no remaining Eton Pharmaceutcials position as of Q2 2023 after selling out during the quarter.
  • Lido Advisors sold 44,000 Eton Pharmaceutcials shares in Q2 2023, an estimated $169K.
  • Lido Advisors first reported a position in Eton Pharmaceutcials in Q1 2023 and held it in 1 quarter.
  • Lido Advisors's Eton Pharmaceutcials position peaked at $169K in Q1 2023.
  • 33 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q2 2023.

Based on Lido Advisors's 13F filing for Q2 2023, filed 9 Aug 2023.